Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management - MammaPrint, Oncotype DX, IHC4 and Mammostrat:

Read more

COF indicators

Read more

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy):

Read more

Consultation on COF indicators:

Read more

Consultation on COF indicators:

Read more

Draft NICE guidance says more evidence needed on new tests to guide breast cancer treatment decisions

Read more

Improving access to NICE-approved drugs

Read more

Improving access to NICE-approved drugs

Read more

NICE consults on a new treatment for prostate cancer

Read more

Public asked for their views on Commissioning Outcomes Framework (COF)

Read more

Public asked for their views on Commissioning Outcomes Framework (COF)

Read more

Brain cooling for newborn babies improved following NICE guidance

Read more

Brain cooling for newborn babies improved following NICE guidance

Read more

2013/14 COF consultation opens

Read more

NICE to have 'key role' in adoption of genetic tests by NHS

Read more

NICE to have 'key role' in adoption of genetic tests by NHS

Read more

Planning service delivery

Read more

Spending to save - public health

Read more

Reducing inefficiency

Read more

Summary of guidance important for general practice

Read more